Cargando…

Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study

BACKGROUND AND AIMS: Clinical data regarding alendronate jelly are limited. We compared the efficacy and safety of once‐weekly alendronate oral jelly with once‐weekly alendronate tablet formulations in the context of primary osteoporosis. METHODS: In this 6‐month, open‐label, prospective, observatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Okimoto, Nobukazu, Uemura, Yukari, Yoshioka, Toru, Arita, Shinobu, Tsurukami, Hiroshi, Otomo, Hajime, Nishida, Satoshi, Ogawa, Takayuki, Hirao, Ken, Ikeda, Satoshi, Matsumoto, Hidehiro, Toten, Yoriko, Katae, Yuji, Okazaki, Yuichi, Nakagawa, Tsuyoshi, Sakai, Akinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346986/
https://www.ncbi.nlm.nih.gov/pubmed/30697599
http://dx.doi.org/10.1002/hsr2.107
_version_ 1783389865243574272
author Okimoto, Nobukazu
Uemura, Yukari
Yoshioka, Toru
Arita, Shinobu
Tsurukami, Hiroshi
Otomo, Hajime
Nishida, Satoshi
Ogawa, Takayuki
Hirao, Ken
Ikeda, Satoshi
Matsumoto, Hidehiro
Toten, Yoriko
Katae, Yuji
Okazaki, Yuichi
Nakagawa, Tsuyoshi
Sakai, Akinori
author_facet Okimoto, Nobukazu
Uemura, Yukari
Yoshioka, Toru
Arita, Shinobu
Tsurukami, Hiroshi
Otomo, Hajime
Nishida, Satoshi
Ogawa, Takayuki
Hirao, Ken
Ikeda, Satoshi
Matsumoto, Hidehiro
Toten, Yoriko
Katae, Yuji
Okazaki, Yuichi
Nakagawa, Tsuyoshi
Sakai, Akinori
author_sort Okimoto, Nobukazu
collection PubMed
description BACKGROUND AND AIMS: Clinical data regarding alendronate jelly are limited. We compared the efficacy and safety of once‐weekly alendronate oral jelly with once‐weekly alendronate tablet formulations in the context of primary osteoporosis. METHODS: In this 6‐month, open‐label, prospective, observational study, Japanese patients aged ≥60 years with primary osteoporosis were included from 14 primary care centres in Japan. The effects of once‐weekly alendronate oral jelly and tablet formulations on bone mineral density (BMD), bone turnover markers, and quality of life related to gastrointestinal symptoms were assessed at baseline and 6 months. Treatment was allocated by patient preference. This potentially confounding factor was adjusted for statistically. RESULTS: In total, 170 patients were enrolled (jelly, n = 97; tablet, n = 73). Mean percent changes in radius, lumbar spine, femoral neck, and hip BMD were similar in both treatment groups at 6 months. Both formulations decreased tartrate‐resistant acid phosphatase 5b (TRACP‐5b) and procollagen 1 N‐terminal peptide (P1NP) between baseline and 6 months (by about 50% and 60%, respectively); no significant differences in mean changes were noted in these markers between groups. At 6 months, no significant differences were noted in visual analogue scale or EuroQOL five‐dimension questionnaire scores between groups. The jelly group had significantly lower scores than the tablet group in the Izumo scale domains of heartburn (−0.81, P = 0.0040), epigastralgia (−0.94, P = 0.0003), and epigastric fullness (−0.49, P = 0.044). During treatment, more patients discontinued for upper gastrointestinal symptoms in the tablet group (n = 4) than the jelly group (n = 1). CONCLUSIONS: Once‐weekly alendronate oral jelly 35 mg may be a suitable alternative therapeutic agent for primary osteoporosis in Japan.
format Online
Article
Text
id pubmed-6346986
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63469862019-01-29 Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study Okimoto, Nobukazu Uemura, Yukari Yoshioka, Toru Arita, Shinobu Tsurukami, Hiroshi Otomo, Hajime Nishida, Satoshi Ogawa, Takayuki Hirao, Ken Ikeda, Satoshi Matsumoto, Hidehiro Toten, Yoriko Katae, Yuji Okazaki, Yuichi Nakagawa, Tsuyoshi Sakai, Akinori Health Sci Rep Research Articles BACKGROUND AND AIMS: Clinical data regarding alendronate jelly are limited. We compared the efficacy and safety of once‐weekly alendronate oral jelly with once‐weekly alendronate tablet formulations in the context of primary osteoporosis. METHODS: In this 6‐month, open‐label, prospective, observational study, Japanese patients aged ≥60 years with primary osteoporosis were included from 14 primary care centres in Japan. The effects of once‐weekly alendronate oral jelly and tablet formulations on bone mineral density (BMD), bone turnover markers, and quality of life related to gastrointestinal symptoms were assessed at baseline and 6 months. Treatment was allocated by patient preference. This potentially confounding factor was adjusted for statistically. RESULTS: In total, 170 patients were enrolled (jelly, n = 97; tablet, n = 73). Mean percent changes in radius, lumbar spine, femoral neck, and hip BMD were similar in both treatment groups at 6 months. Both formulations decreased tartrate‐resistant acid phosphatase 5b (TRACP‐5b) and procollagen 1 N‐terminal peptide (P1NP) between baseline and 6 months (by about 50% and 60%, respectively); no significant differences in mean changes were noted in these markers between groups. At 6 months, no significant differences were noted in visual analogue scale or EuroQOL five‐dimension questionnaire scores between groups. The jelly group had significantly lower scores than the tablet group in the Izumo scale domains of heartburn (−0.81, P = 0.0040), epigastralgia (−0.94, P = 0.0003), and epigastric fullness (−0.49, P = 0.044). During treatment, more patients discontinued for upper gastrointestinal symptoms in the tablet group (n = 4) than the jelly group (n = 1). CONCLUSIONS: Once‐weekly alendronate oral jelly 35 mg may be a suitable alternative therapeutic agent for primary osteoporosis in Japan. John Wiley and Sons Inc. 2018-12-12 /pmc/articles/PMC6346986/ /pubmed/30697599 http://dx.doi.org/10.1002/hsr2.107 Text en © 2018 The Authors. Health Science Reports published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Okimoto, Nobukazu
Uemura, Yukari
Yoshioka, Toru
Arita, Shinobu
Tsurukami, Hiroshi
Otomo, Hajime
Nishida, Satoshi
Ogawa, Takayuki
Hirao, Ken
Ikeda, Satoshi
Matsumoto, Hidehiro
Toten, Yoriko
Katae, Yuji
Okazaki, Yuichi
Nakagawa, Tsuyoshi
Sakai, Akinori
Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title_full Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title_fullStr Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title_full_unstemmed Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title_short Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
title_sort treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for japanese patients with primary osteoporosis: an open‐label, prospective, observational study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346986/
https://www.ncbi.nlm.nih.gov/pubmed/30697599
http://dx.doi.org/10.1002/hsr2.107
work_keys_str_mv AT okimotonobukazu treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT uemurayukari treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT yoshiokatoru treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT aritashinobu treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT tsurukamihiroshi treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT otomohajime treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT nishidasatoshi treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT ogawatakayuki treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT hiraoken treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT ikedasatoshi treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT matsumotohidehiro treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT totenyoriko treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT kataeyuji treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT okazakiyuichi treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT nakagawatsuyoshi treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy
AT sakaiakinori treatmentwithonceweeklyalendronateoraljellycomparedwithonceweeklyalendronateoraltabletforjapanesepatientswithprimaryosteoporosisanopenlabelprospectiveobservationalstudy